Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.44 |
| ▸ | PPARA | Q07869 | 15/20 | 0.42 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706705 | 0.85 | PPARA (0.48) | PPARGPPARAPPARD | |
| SCHEMBL2706681 | 0.81 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL31609761 | 0.80 | MEN1 (0.49) | MEN1KMT2ALMNA | |
| SCHEMBL2706702 | 0.80 | MEN1 (0.49) | MEN1KMT2ALMNA | |
| SCHEMBL202033 | 0.75 | PPARG (0.51) | PPARGPPARALMNA | |
| SCHEMBL200994 | 0.74 | PPARG (0.54) | PPARGPPARA | |
| SCHEMBL202507 | 0.73 | MRGPRX4 (0.53) | LMNA | |
| SCHEMBL201335 | 0.70 | L3MBTL1 (0.64) | MEN1KMT2ALMNA | |
| SCHEMBL202627 | 0.69 | MAOB (0.56) | MEN1KMT2ALMNA | |
| SCHEMBL10367150 | 0.69 | PPARG (0.64) | PPARGPPARAPPARDPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | PPARG 3846/4885PPARA 2979/4885PPARD 3683/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PPARG 3402/4885PPARA 3049/4885PPARD 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.